From July 1, 2022 to December 31, 2022, the company has repurchased 0 shares, representing 0% for HKD 0 million. With this, the company has completed the repurchase of 229,000 shares, representing 0.03% for HKD 0.21 million under the buyback announced on June 2, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 HKD | -0.91% |
|
-6.84% | -20.44% |
05-31 | Chinese Regulators Accept Fusen Pharmaceutical’s Drug Application | MT |
04-04 | Fusen Pharmaceutical's Type 2 Diabetes Drug Application Accepted by Chinese Regulator | MT |
1st Jan change | Capi. | |
---|---|---|
-20.44% | 104M | |
+19.51% | 42.97B | |
+27.49% | 22.16B | |
+19.29% | 15.45B | |
+20.33% | 14.56B | |
+55.51% | 13.03B | |
-0.05% | 6.79B | |
-11.37% | 6.46B | |
+17.73% | 5.87B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- 1652 Stock
- News Fusen Pharmaceutical Company Limited
- Tranche Update on Fusen Pharmaceutical Company Limited's Equity Buyback Plan announced on June 2, 2022.